A validated gene expression profile for detecting clinical outcome in breast cancer using artificial neural networks.
AuthorsLancashire, Lee J
Powe, D G
Reis-Filho, J S
Abdel-Fatah, T M
Green, Anthony R
Paish, E C
Rees, Robert C
Ellis, I O
Ball, Graham R
AffiliationClinical and Experimental Pharmacology, Paterson Institute for Cancer Research, University of Manchester, Manchester, M20 4BX, UK, firstname.lastname@example.org.
MetadataShow full item record
AbstractGene expression microarrays allow for the high throughput analysis of huge numbers of gene transcripts and this technology has been widely applied to the molecular and biological classification of cancer patients and in predicting clinical outcome. A potential handicap of such data intensive molecular technologies is the translation to clinical application in routine practice. In using an artificial neural network bioinformatic approach, we have reduced a 70 gene signature to just 9 genes capable of accurately predicting distant metastases in the original dataset. Upon validation in a follow-up cohort, this signature was an independent predictor of metastases free and overall survival in the presence of the 70 gene signature and other factors. Interestingly, the ANN signature and CA9 expression also split the groups defined by the 70 gene signature into prognostically distinct groups. Subsequently, the presence of protein for the principal prognosticator gene was categorically assessed in breast cancer tissue of an experimental and independent validation patient cohort, using immunohistochemistry. Importantly our principal prognosticator, CA9, showed that it is capable of selecting an aggressive subgroup of patients who are known to have poor prognosis.
CitationA validated gene expression profile for detecting clinical outcome in breast cancer using artificial neural networks. 2009: Breast Cancer Res. Treat.
JournalBreast Cancer Research and Treatment
- Hypoxia-regulated carbonic anhydrase IX expression is associated with poor survival in patients with invasive breast cancer.
- Authors: Hussain SA, Ganesan R, Reynolds G, Gross L, Stevens A, Pastorek J, Murray PG, Perunovic B, Anwar MS, Billingham L, James ND, Spooner D, Poole CJ, Rea DW, Palmer DH
- Issue date: 2007 Jan 15
- Gene expression profiles associated with the presence of a fibrotic focus and the growth pattern in lymph node-negative breast cancer.
- Authors: Van den Eynden GG, Smid M, Van Laere SJ, Colpaert CG, Van der Auwera I, Bich TX, van Dam P, den Bakker MA, Dirix LY, Van Marck EA, Vermeulen PB, Foekens JA
- Issue date: 2008 May 15
- CA IX is an independent prognostic marker in premenopausal breast cancer patients with one to three positive lymph nodes and a putative marker of radiation resistance.
- Authors: Brennan DJ, Jirstrom K, Kronblad A, Millikan RC, Landberg G, Duffy MJ, Rydén L, Gallagher WM, O'Brien SL
- Issue date: 2006 Nov 1
- Molecular characteristics and metastasis predictor genes of triple-negative breast cancer: a clinical study of triple-negative breast carcinomas.
- Authors: Kuo WH, Chang YY, Lai LC, Tsai MH, Hsiao CK, Chang KJ, Chuang EY
- Issue date: 2012
- Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival.
- Authors: Hui EP, Chan AT, Pezzella F, Turley H, To KF, Poon TC, Zee B, Mo F, Teo PM, Huang DP, Gatter KC, Johnson PJ, Harris AL
- Issue date: 2002 Aug